Global Custom Market Research Reports Provider Company

phone

Cystic Fibrosis - Pipeline Review, H2 2018

  • Published Date: 11 Sep 2018
  • Number of Pages: 435
  • Category: Pharmaceuticals
  • Country: Global
Cystic Fibrosis - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H2 2018, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the bodys organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 29, 27, 60 and 30 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct
Introduction 6
Cystic Fibrosis - Overview 7
Cystic Fibrosis - Therapeutics Development 8
Cystic Fibrosis - Therapeutics Assessment 29
Cystic Fibrosis - Companies Involved in Therapeutics Development 41
Cystic Fibrosis - Drug Profiles 76
Cystic Fibrosis - Dormant Projects 395
Cystic Fibrosis - Discontinued Products 403
Cystic Fibrosis - Product Development Milestones 404
Appendix 417

List Of Tables


Number of Products under Development for Cystic Fibrosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Cystic Fibrosis - Pipeline by 4D Molecular Therapeutics Inc, H2 2018
Cystic Fibrosis - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2018
Cystic Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H2 2018
Cystic Fibrosis - Pipeline by AGILeBiotics BV, H2 2018
Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2018
Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2018
Cystic Fibrosis - Pipeline by AmpliPhi Biosciences Corp, H2 2018
Cystic Fibrosis - Pipeline by Antabio SAS, H2 2018
Cystic Fibrosis - Pipeline by Arch Biopartners Inc, H2 2018
Cystic Fibrosis - Pipeline by Arcturus Therapeutics Ltd, H2 2018
Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals Inc, H2 2018
Cystic Fibrosis - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2018
Cystic Fibrosis - Pipeline by AstraZeneca Plc, H2 2018
Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Cystic Fibrosis - Pipeline by Calithera Biosciences Inc, H2 2018
Cystic Fibrosis - Pipeline by Catabasis Pharmaceuticals Inc, H2 2018
Cystic Fibrosis - Pipeline by Celtaxsys Inc, H2 2018
Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2018
Cystic Fibrosis - Pipeline by Cilian AG, H2 2018
Cystic Fibrosis - Pipeline by CRISPR Therapeutics, H2 2018
Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018
Cystic Fibrosis - Pipeline by Cyclenium Pharma Inc, H2 2018
Cystic Fibrosis - Pipeline by DiscoveryBiomed Inc, H2 2018
Cystic Fibrosis - Pipeline by Editas Medicine Inc, H2 2018
Cystic Fibrosis - Pipeline by Eloxx Pharmaceuticals Inc, H2 2018
Cystic Fibrosis - Pipeline by Enterprise Therapeutics Ltd, H2 2018
Cystic Fibrosis - Pipeline by Errant Gene Therapeutics LLC, H2 2018
Cystic Fibrosis - Pipeline by ethris GmbH, H2 2018
Cystic Fibrosis - Pipeline by Evaxion Biotech ApS, H2 2018
Cystic Fibrosis - Pipeline by Galapagos NV, H2 2018
Cystic Fibrosis - Pipeline by Generation Bio Corp, H2 2018
Cystic Fibrosis - Pipeline by Grifols SA, H2 2018
Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2018
Cystic Fibrosis - Pipeline by Helperby Therapeutics Group Ltd, H2 2018
Cystic Fibrosis - Pipeline by Homology Medicines, Inc., H2 2018
Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H2 2018
Cystic Fibrosis - Pipeline by ID Pharma Co Ltd, H2 2018
Cystic Fibrosis - Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Cystic Fibrosis - Pipeline by Immun System IMS AB, H2 2018
Cystic Fibrosis - Pipeline by Insmed Inc, H2 2018
Cystic Fibrosis - Pipeline by Invion Ltd, H2 2018
Cystic Fibrosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Cystic Fibrosis - Pipeline by JHL Biotech Inc, H2 2018
Cystic Fibrosis - Pipeline by Johnson & Johnson, H2 2018
Cystic Fibrosis - Pipeline by Kamada Ltd, H2 2018
Cystic Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018
Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H2 2018
Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc, H2 2018
Cystic Fibrosis - Pipeline by Lexicon Pharmaceuticals Inc, H2 2018
Cystic Fibrosis - Pipeline by Microbion Corp, H2 2018
Cystic Fibrosis - Pipeline by Novabiotics Ltd, H2 2018

List Of Figures


Number of Products under Development for Cystic Fibrosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018 According to the recently published report Transmembrane Prolyl 4 Hydroxylase -

View Report

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018 CD40 Ligand (T

View Report

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2018 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports